^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ISB 2001
i
Other names: ISB 2001
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Glenmark
Drug class:
CD3 agonist, CD38 inhibitor, BCMA inhibitor
Related drugs:
5ms
Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma (ASH 2023)
Instead, we generated datasets employing in vitro and in vivo models for ISB 2001 and teclistamab (possessing a similar mode of action). However, to our knowledge this is the first time that a starting dose in clinical studies of a trispecific TCE, lacking species cross-reactivity and therefore a GLP toxicology preclinical package, has been derived based on integrated preclinical data analysis utilizing a QSP model. Clinical evaluation of ISB 2001 is ongoing in a phase I dose escalation and dose expansion study in subjects with relapsed/refractory MM (NCT05862012).
P1 data • Preclinical • IO biomarker • Trispecific
|
CD38 (CD38 Molecule)
|
Tecvayli (teclistamab-cqyv) • ISB 2001
12ms
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=80, Not yet recruiting, Ichnos Sciences SA
New P1 trial
|
ISB 2001
Share via
